| Pasireotide studied in …STUDIED_INderived28 of 28show fewer |
|---|
| → studied in | NCT06295952Phase 2 · recruiting A Study of Pasireotide in People With Prolactinoma · 28 trials list this drug (3 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01313559Phase 2 · terminated Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer · 28 trials list this drug (3 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06456359Phase 2 · recruiting Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor · 28 trials list this drug (3 active) | — | — | Desmoplastic Small Round Cell Tumor,Synovial Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01794793Phase 4 · completed Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies · 28 trials list this drug (3 active) | — | — | Pituitary Gland Neoplasm,Neuroendocrine Tumor,Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04826432Phase 2 · terminated Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis · 28 trials list this drug (3 active) | — | — | Peritoneal Carcinomatosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02779257Phase 4 · withdrawn Pasireotide Treatment for Neuroendocrine Tumor · 28 trials list this drug (3 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02215070Phase 2 · completed Pasireotide in Prevention of GI Toxicity · 28 trials list this drug (3 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03053284Phase 2 · withdrawn Pasireotide in Hyperinsulinemic Hypoglycemia · 28 trials list this drug (3 active) | — | — | Pancreatic Insulinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01468532Phase 1/Phase 2 · completed Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer · 28 trials list this drug (3 active) | — | — | Prostate Adenocarcinoma,Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01270321Phase 2 · completed Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer · 28 trials list this drug (3 active) | — | — | Malignant Thyroid Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00446082Phase 1 · completed Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease · 28 trials list this drug (3 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01646684Phase 1 · completed Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer · 28 trials list this drug (3 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02775227Phase 4 · active not recruiting HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications · 28 trials list this drug (3 active) | — | — | Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01590199Phase 1 · completed Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs · 28 trials list this drug (3 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01469572Phase 1 · completed Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases · 28 trials list this drug (3 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01137682Phase 3 · completed Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly · 28 trials list this drug (3 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02780882Phase 2 · withdrawn SOM230 Ectopic ACTH-producing Tumors · 28 trials list this drug (3 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01639352Phase 2 · completed Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma · 28 trials list this drug (3 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01356862Phase 2 · completed Pasireotide LAR Administration in Lymphocele Prevention After Axillary Node Dissection for Breast Cancer · 28 trials list this drug (3 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01617733Phase 2 · terminated Pasireotide Therapy in Patients With Nelson's Syndrome · 28 trials list this drug (3 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00804336Phase 1 · completed Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors · 28 trials list this drug (3 active) | — | — | Neuroendocrine Tumor,Pancreatic Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01620138Phase 2/Phase 3 · completed Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas · 28 trials list this drug (3 active) | — | — | Lactotroph Pituitary Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01488487Phase 2 · completed Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma · 28 trials list this drug (3 active) | — | — | Adult Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01329289Phase 2 · withdrawn SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma · 28 trials list this drug (3 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00994110Phase 3 · completed Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess · 28 trials list this drug (3 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00690430Phase 3 · completed Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease · 28 trials list this drug (3 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01234974Phase 2 · withdrawn IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus · 28 trials list this drug (3 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00088595Phase 2 · completed Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors · 28 trials list this drug (3 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |